Arhaus price target raised to $15 from $14 at Piper Sandler
Piper Sandler raised the firm’s price target on Arhaus (ARHS) to $15 from $14 and keeps an Overweight rating on the shares ...
Hosted on MSN1d
Piper Sandler Initiates Coverage of ResMed (RMD) with Neutral Recommendation
Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed (NYSE:RMD) with a Neutral recommendation.
Piper Sandler: Mid-Market But Better Indexed To Lax FTC (Rating Upgrade)
Piper Sandler Companies is gaining traction with a recovering market. Find out why PIPR stock is becoming an attractive ...
Nektar Therapeutics (NKTR) Gets a Buy from Piper Sandler
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report) today and set a price target of ...
1 Magnificent Dividend Growth Stock That Could Soar 20% in 2025, According to a Couple of Wall Street Analysts
On Monday, Jan. 7, Michael Lavery at Piper Sandler initiated coverage of the beverage giant, with an overweight rating and a ...
Coca-Cola and PepsiCo land bull ratings at Piper Sandler
Piper Sandler dipped into the beverage sector on Tuesday by issuing new Overweight ratings on Coca-Cola (NYSE:KO) and PepsiCo ...
Kenvue stock still has 'ample room': Piper Sandler
Despite recent share appreciation, Piper Sandler believes there is still significant upside for Kenvue. “Though shares have ...
Nasdaq1mon
Poseida Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded Poseida Therapeutics (PSTX) to Neutral from Overweight with an unchanged price target of $10 following Roche’s announced acquisition for $9 per share in cash and $4 per ...
Amplitude, Asana see bullish views at Piper Sandler, stocks climb
Piper Sandler upgraded Amplitude and Asana to Overweight from Neutral, while highlighting trends for the software industry.
We are focusing more on quality value than quality growth this year, says Piper Sandler's Kantrowitz
Michael Kantrowitz, Piper Sandler chief investment strategist, joins 'The Exchange' to discuss why higher rates pose the biggest risks to markets and more.